News and Events

NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases

Apr 21, 2022

NovaBiotics to Present at the H.C. Wainwright BioConnect Conference

Jan 4, 2022

NovaBiotics Announces First Patient Enrolment into the Cysteamine Domain of REMAP-CAP

Dec 8, 2021

NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference

Nov 1, 2021

NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology

Oct 5, 2021

NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF)

Sep 23, 2021

NovaBiotics Highlights Advantages of Novel Immune-Based Approach to Combatting Fungal and Bacterial Infectious Diseases at Peptide Therapeutics Forum 2021

Aug 25, 2021

NovaBiotics Announces Presentation at Upcoming Peptide Therapeutics Forum 2021

Aug 2, 2021

NovaBiotics Named as One of Scotland’s Top Ten Biotech Companies to Watch Out For

Jul 7, 2021

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

Jun 21, 2021